Department of Hematology, Suqian First People's Hospital Affiliated to Nanjing Medical University, Suqian, People's Republic of China.
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.
Hematology. 2022 Dec;27(1):1062-1068. doi: 10.1080/16078454.2022.2121103.
Herein, we aimed to determine the clinical efficacy of recombinant human thrombopoietin (rhTPO) combined with glucocorticoids for treating immune thrombocytopenia (ITP).
Clinical data of 87 patients with ITP admitted to our hospital were retrospectively analyzed, and patients were divided into two groups according to the treatment employed: 42 patients in the control group (CG) were prescribed glucocorticoids, and 45 patients in the study group (SG) received rhTPO combined with glucocorticoids.
The total effective treatment rate in the SG (95.56%) was higher than that in the CG (76.19%) ( < 0.05) The SG achieved a platelet (PLT) count > 50 × 10/L faster and required fewer PLT transfusions than the CG ( < 0.05). At 1, 7, and 14 days after treatment, the PLT count increased in both groups and was higher in the SG than in the CG ( < 0.05). After treatment, CD3+, CD4+, and CD4+/CD8+ T cells increased, whereas CD8 + decreased in both groups, with the SG exhibiting a superior improvement to the CG ( < 0.05). Considering prothrombin time, activated partial thromboplastin time, and fibrinogen, differences between the two groups were not statistically significant, both before and after treatment ( > 0.05).
rhTPO combined with glucocorticoids for treating ITP can effectively enhance the therapeutic effect, regulate the T lymphocyte subpopulation, rapidly increase the PLT level, and induce no significant effect on the coagulation function of patients, with good safety and high clinical promotion value.
本研究旨在探讨重组人血小板生成素（rhTPO）联合糖皮质激素治疗免疫性血小板减少症（ITP）的临床疗效。
回顾性分析我院收治的 87 例 ITP 患者的临床资料，根据治疗方法分为两组，对照组（CG）42 例患者给予糖皮质激素治疗，观察组（SG）45 例患者给予 rhTPO 联合糖皮质激素治疗。
SG 的总有效治疗率（95.56%）高于 CG（76.19%）（<0.05），SG 血小板（PLT）计数>50×10/L 更快，PLT 输注次数更少（<0.05）。治疗后 1、7、14 天，两组 PLT 计数均增加，SG 高于 CG（<0.05）。治疗后，两组 CD3+、CD4+、CD4+/CD8+T 细胞均增加，CD8+细胞减少，SG 改善优于 CG（<0.05）。两组治疗前后凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原比较，差异均无统计学意义（>0.05）。
rhTPO 联合糖皮质激素治疗 ITP 可有效增强疗效，调节 T 淋巴细胞亚群，迅速提高 PLT 水平，对患者凝血功能无明显影响，安全性好，临床推广价值高。
